Herpes simplex virus us3 and icp4 as inhibitors of apoptosis
CA 2286859 A1 · Owner: Arch Development Corporation · Inventors: Roizman, Bernard; Leopardi, Rosario
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function as indicated by , studies using temperature sensitive mutants of ICP4 that have transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene such as an .alpha.4 gene, methods for inhibiting ICP4's apoptosis-inhibiting function and methods for , the production of recombinant proteins and treatment of HSV infections. Further, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 16, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 16, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 16, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.